Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance.
about
Drug resistance analysis by next generation sequencing in LeishmaniaNew Approaches to Overcome Transport Related Drug Resistance in Trypanosomatid ParasitesPlasticity of the Leishmania genome leading to gene copy number variations and drug resistanceMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisP4-ATPases: lipid flippases in cell membranesMultiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencingGeneration of Leishmania hybrids by whole genomic DNA transformationIn vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasisFitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania majorDevelopment and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Screening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity.Different Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct MechanismsDrug resistance in leishmaniasisDrug resistance in eukaryotic microorganisms.In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.Polymeric Nanoparticles of Brazilian Red Propolis Extract: Preparation, Characterization, Antioxidant and Leishmanicidal Activity.Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance.P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors.A phospholipid uptake system in the model plant Arabidopsis thaliana.Disruption of the lipid-transporting LdMT-LdRos3 complex in Leishmania donovani affects membrane lipid asymmetry but not host cell invasionImmunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.A putative plant aminophospholipid flippase, the Arabidopsis P4 ATPase ALA1, localizes to the plasma membrane following association with a β-subunit.In vitro and in vivo interactions between miltefosine and other antileishmanial drugsTransbilayer dynamics of phospholipids in the plasma membrane of the Leishmania genusLABCG2, a new ABC transporter implicated in phosphatidylserine exposure, is involved in the infectivity and pathogenicity of LeishmaniaStructures, targets and recent approaches in anti-leishmanial drug discovery and development.Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug effluxIn vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococciLeishmania is not prone to develop resistance to tamoxifen.Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management.Cos-Seq for high-throughput identification of drug target and resistance mechanisms in the protozoan parasite Leishmania.Genomic Appraisal of the Multifactorial Basis for In Vitro Acquisition of Miltefosine Resistance in Leishmania donovaniA new ABC half-transporter in Leishmania major is involved in resistance to antimony.In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.Treatment of leishmaniasis with miltefosine: 2008 status.A mitochondrial HSP70 (HSPA9B) is linked to miltefosine resistance and stress response in Leishmania donovani.Transporters for drug delivery and as drug targets in parasitic protozoa.Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species.Untargeted metabolomic analysis of miltefosine action in Leishmania infantum reveals changes to the internal lipid metabolism.
P2860
Q26851222-5B8336B1-E0FF-4B5B-8A38-B5CFD8181FD7Q28068159-6A5FB469-381D-4D83-B727-08FA13D1BBEEQ28074697-CD8EB8B3-BAE5-417F-9D4D-01F4828577B3Q28271849-DE0E8CB6-ED7F-454B-B7CE-F62C57D86BA5Q28388229-35175A8E-410F-4A7F-8167-F4585481B489Q28480626-1689EF4A-6D3B-49E1-8C57-C6FF646ACE43Q28483925-16A445D5-B595-46EC-9589-66900F511C2AQ28540828-6A59C6A7-10CF-4CC7-9822-E2656C224676Q28546940-5839EBF6-12F3-463A-865E-91BE2B036EA8Q28548536-5E297B94-48D5-45E4-BDC0-F45D6E05D7E3Q28554770-8FF843F2-5C22-4700-91B6-1B3610001055Q29616242-15E81CA1-FE61-4889-920D-B5E36C562749Q30248243-9A674786-1226-41B9-8577-C9B560FA9AEEQ30380900-ED35B5DA-852D-4BBE-8924-423241FEF11DQ30382963-274846DA-CB77-40EA-9CB4-EDE6883EF2C4Q33230937-873E440E-5ECB-460F-8739-F7FC9FB9E427Q33268817-503EC79F-28B8-4A35-872A-0A2E5295E379Q33361191-B24BBC82-EF63-4AA6-AE2A-66757BB72B57Q33701743-1666CEAF-6CAC-40ED-A119-D77176581C13Q33749424-FB54A982-DCF5-4B0D-B670-988A2F038F09Q34238377-0AD14DC1-E4C3-41F3-8429-A6BF08609DE6Q34301638-C9FE44DE-49D8-46C9-A4C5-76077E857D6AQ34576787-D0E994CF-6B72-4952-8645-734FBCD24D73Q34702464-B2CBA6BE-5DE5-4B1C-B078-8E04F77B87B0Q35012968-07323A7F-BB20-4935-B08A-E55622559C80Q35023368-4DFE3818-4FF7-41CF-B49E-7313AB9A7762Q35759108-74F17870-5591-4353-BEBD-7C59E41E3121Q35801671-31E6CA9E-4128-4338-BDA6-D0ABA7F4B82AQ36001763-B041C3B7-920D-431E-94E0-A6F90D5A5F37Q36564101-2BB9D3DE-47A3-4D26-A0B3-3E76275BDDEBQ36645795-2225AE5B-1F19-490D-B461-78873964E08AQ36957213-196B9D50-0D6E-46D1-9C09-AE020766825BQ37023262-67CD0E10-8148-4A82-9305-D87CF5C6B3BEQ37036630-1E891FE1-4675-4994-8D33-7A09F557EB02Q37072017-AA39EDA7-D55E-4B0B-AB29-2A25178793F1Q37249719-70C5BCFA-96F8-45BA-9E09-2E804F8D2B86Q37465295-B4E0BECF-446F-4DF6-A7BD-87A7D1B42FB5Q37538522-F72A8322-950B-41AA-8436-82C95689601BQ37544280-D90C088A-77A0-4424-BC18-DF93E9593172Q37613357-E45FBB50-90EA-45E7-8A93-49FB8E1EE2A5
P2860
Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Functional cloning of the milt ...... a involved in drug resistance.
@en
Functional cloning of the milt ...... a involved in drug resistance.
@nl
type
label
Functional cloning of the milt ...... a involved in drug resistance.
@en
Functional cloning of the milt ...... a involved in drug resistance.
@nl
prefLabel
Functional cloning of the milt ...... a involved in drug resistance.
@en
Functional cloning of the milt ...... a involved in drug resistance.
@nl
P2860
P356
P1476
Functional cloning of the milt ...... a involved in drug resistance.
@en
P2093
F Javier Pérez-Victoria
Santiago Castanys
P2860
P304
49965-49971
P356
10.1074/JBC.M308352200
P407
P577
2003-09-27T00:00:00Z